Bacterial Infections among Patients with Chronic Diseases at a Tertiary Care Hospital in Saudi Arabia

Infections caused by multi-drug-resistant bacteria in patients with chronic diseases have been associated with high mortality and morbidity. While few reports have evaluated bacterial infections in multiple chronic disease patients, the focus of the current study was to investigate the prevalence of...

Full description

Bibliographic Details
Main Authors: Abdulrahman S. Bazaid, Ahmed A. Punjabi, Abdu Aldarhami, Husam Qanash, Ghaida Alsaif, Hattan Gattan, Heba Barnawi, Bandar Alharbi, Abdulaziz Alrashidi, Abdulaziz Alqadi
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Microorganisms
Subjects:
Online Access:https://www.mdpi.com/2076-2607/10/10/1907
Description
Summary:Infections caused by multi-drug-resistant bacteria in patients with chronic diseases have been associated with high mortality and morbidity. While few reports have evaluated bacterial infections in multiple chronic disease patients, the focus of the current study was to investigate the prevalence of bacterial infections and the susceptibility profiles of causative strains among various groups of patients suffering from chronic diseases. Microbiological reports of patients suffering from cancer, diabetes mellitus, cardiovascular diseases, kidney diseases, and skin burns were retrospectively collected from a tertiary hospital in Saudi Arabia. Approximately 54.2% of recruited patients were males, and positive urine was the most prevalent specimen associated with kidney disease patients (25%)<i>. Escherichia coli</i> isolates were predominant among cardiovascular, kidney, and cancer patients. <i>Staphylococcus aureus</i> was commonly detected in diabetics and those with burns. Although resistance patterns varied based on the type of specimens and underlying diseases, <i>Escherichia coli</i> showed limited resistance to colistin, carbapenems, and tigecycline, while <i>S. aureus</i> demonstrated susceptibility to ciprofloxacin, gentamicin, and rifampin. These observations are crucial for clinicians and policymakers to ensure effective treatment plans and improve outcomes in these patients with comorbidity.
ISSN:2076-2607